Alkermes Acquires Avadel for $2.3B, Expanding into Sleep Medicine
Event summary
- Alkermes completed the acquisition of Avadel Pharmaceuticals for $2.3B on February 12, 2026.
- The deal adds Avadel’s FDA-approved LUMRYZ® to Alkermes’ portfolio, targeting narcolepsy.
- Alkermes financed the acquisition with $775M in cash and $1.525B in term loans due in 2031.
- LUMRYZ® has significant growth potential with over 50,000 oxybate-eligible narcolepsy patients in the U.S.
- Alkermes expects the acquisition to be accretive in 2026, with transaction-related costs of $40M in Q1.
The big picture
Alkermes’ acquisition of Avadel marks a strategic pivot into the sleep medicine market, leveraging Avadel’s established commercial infrastructure and FDA-approved LUMRYZ®. This move positions Alkermes to capitalize on the growing demand for narcolepsy treatments, while also expanding its capabilities in rare diseases. The $2.3B deal underscores Alkermes’ commitment to long-term value creation, though it introduces significant debt and integration challenges.
What we're watching
- Integration Challenges
- How Alkermes will integrate Avadel’s commercial organization and R&D portfolio into its existing operations.
- Debt Management
- Whether Alkermes can pay down the $1.525B in term loans quickly with cash flows from the business.
- Pipeline Progress
- The pace at which Alkermes advances its late-stage development pipeline for central disorders of hypersomnolence.
Related topics